Cadila Pharmaceuticals
 | |
| Private company | |
| Industry | Pharmaceuticals |
| Founded | 1951 |
| Founder | Mr.Indravadan A. Modi |
| Headquarters | Ahmedabad, Gujarat, India |
Key people |
Dr. Rajiv Modi (Chairman and Managing Director) |
| Products | Branded Formulations, Generic drugs |
| Services | Contract Research, Contract Manufacturings |
| Website |
www |
Cadila Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad, Gujarat, founded in 1951 with a mission to make affordable healthcare for humanity.
Cadila Pharmaceuticals manufactures and sells finished formulations and active pharmaceutical ingredients (APIs) in 85 countries. The company offers formulations across therapeutic areas, such as cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, antidiabetics and immunologicals.
Company
Cadila Laboratories was established by Mr. Indravadan A. Modi along with Mr. Raman Patel in 1951 in Ahmedabad. In 1995 the company was restructured into two separate companies. These were Cadila Pharmaceuticals to be managed by Mr. Indravadan Modi and Cadila Healthcare which went to his erstwhile partner Mr. Raman Patel. Dr. Rajiv Modi, son of Mr. Indravadan Modi is the current chairman and managing director of Cadila Pharmaceuticals Limited.[1]
Manufacturing
Cadila Pharmaceuticals has its formulation manufacturing facilities at Dholka, Gujarat (India); Samba, Jammu (India) and at Addis Ababa, Ethiopia. The 2 API manufacturing facilities are located at Ankleshwar, Gujarat.
The manufacturing facility at Dholka and the API unit at Ankleshwar in Gujarat are USFDA-certified; the overseas manufacturing facility at Ethiopia is the WHO - cGMP compliant facility.[2]
Accreditations
Cadila Pharmaceuticals manufacturing facilities are accredited by WHO-GMP, WHO- Geneva (GDF site for Anti-TB), USFDA, TGA Australia (PIC/S), MHRA-UK, MCC-South Africa, ISO 9001 and ISO 14001.[3]
Research
Cadila Pharmaceuticals has established a dedicated R&D facility, spread over 1,05,000 sq. ft. area at Dholka, Gujarat, India which is manned by 300 scientists.
The firm is the first Indian company to get Investigational New Drug (IND) approval by USFDA for clinical trials to be conducted in India. The company has five IND dossiers filed with the USFDA for pulmonary tuberculosis, lung cancer, prostate cancer, bladder cancer and melanoma. The company has submitted ten ANDAs.[4] Cadila Pharmaceuticals has connections with various institutions for research; Department of Biotechnology, UDSC, New Delhi; IISc, Bangalore; Lala Ram Sarup Institute of TB & Respiratory diseases, New Delhi; RRL, Jammu; CSIR, New Delhi; CDRI, Lucknow; Advanced Transfusion Medicine Research Foundation, Ahmedabad; National Institute of Immunology, New Delhi; Institute of Microbial Technology, Chandigarh; Talwar Research Foundation, New Delhi and Trieste, Italy.[5]
Products & Services
Cadila Pharmaceuticals offers branded and generic formulations covering more than 45 therapeutic segments and 12 specialties. It also offers 50 APIs and intermediates. In the services realm, the company offers Contract Research and Contract Manufacturing.
Cadila Pharmaceuticals is the only Indian manufacturer of natural Streptokinase and Hyaluronic Acid products. The company was also the first in the world to introduce Rabeprazole in IV form – ‘Rabeloc’.[6] In 2009, the world’s first boosted-Rifampicin fixed-dose combination for the treatment of Tuberculosis – ‘Risorine’[7] and world's first drug combination for prevention of Cardiovascular Diseases – ‘Polycap’ were introduced by Cadila Pharmaceuticals.[8] For the patients suffering from Non Small Cell Lung Cancer (NSCLC), company has recently introduced ‘Mycidac-C’ - first in the class active immunotherapy as well as drug targeting Desmocollin.[9] Some of the top brands of the company are Aciloc, Envas, Calcirol, Haem Up, Vasograin, Tricort, Fludac, Rabiloc, Trigan-D and Mycobutol